Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV vaccine (HD-MAP)
- Development stage
- Preclinical
- Lead developer
- Vaxxas
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal
01
Overview
This is a prophylactic vaccine candidate for Respiratory Syncytial Virus (RSV) being developed by Vaxxas in collaboration with SK bioscience. It utilizes Vaxxas' proprietary high-density microarray patch (HD-MAP) technology for needle-free, transdermal delivery. The vaccine features the DS2 antigen, a next-generation RSV antigen licensed from the U.S. National Institutes of Health (NIH), which is designed to provide a more robust and durable immune response compared to the DS-Cav1 antigen used in earlier vaccines. The HD-MAP system consists of thousands of microscopic projections that deliver a dried vaccine formulation directly to the immune-cell-rich layers of the skin, potentially eliminating the need for cold-chain storage and allowing for easier administration.
- Other names
- RSV HD-MAP vaccinenext-generation RSV vaccine patchRSV Vaccine (next-generation)DS2 RSV vaccineDS-2 RSV vaccineDS 2 RSV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV vaccine (HD-MAP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV vaccine (HD-MAP).